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Key Points
• Atrial fibrillation is the most common sustained arrhythmia.
• For patients presenting with their first episode of atrial fibrillation, transthoracic echocardiography is often helpful for initial management and evaluation. Many cardiac disorders associated with atrial fibrillation, including mitral valve disease, hypertensive heart disease [left ventricular (LV) hypertrophy], or focal ischemic heart disease (segmented LV systolic dysfunction) may be recognized by transthoracic echocardiography.
• The absence of both clinical risk factors and structural heart disease in transthoracic echocardiography identifies patients for whom chronic therapy with aspirin as opposed to warfarin may be preferred. Transthoracic echocardiography is not advocated for identification or exclusion of atrial thrombi because of its inability to detail small thrombi and to image the left atrial appendage. For the detection of left atrial thrombi, transesophageal echocardiography (TEE) is superior.
• The author recommends cardioversion for most patients who present with their first episode of atrial fibrillation (assuming the duration of the atrial fibrillation is brief, and reversible potential causes of atrial fibrillation have been treated).
• Patients with persistent atrial fibrillation of more than 1 year and those with a left atrial dimension of more than 6.0 cm are less likely to have long-term maintenance of sinus rhythm.
• Patients with atrial fibrillation for at least 2 days have a 6% risk of cardioversion-related clinical thromboembolism if cardioversion is not preceded by 3 to 4 weeks of warfarin.
• Transesophageal echocardiography may be beneficial in guiding early cardioversion and detecting left atrial thrombi.
• Systemic anticoagulation for 4 weeks after cardioversion inhibits the formation of new thrombi during the recovery of atrial function, and can be used for prophylaxis should the patient revert to atrial fibrillation.
• The presence of an atrial thrombus by TEE confers an adverse prognosis despite maintenance of systemic anticoagulation and avoidance of cardioversion.
Atrial fibrillation is the most common sustained arrhythmia. It is characterized by a lack of organized atrial electrical and mechanical activity. The loss of orderly atrial systolic contraction leads to impaired left ventricular filling with resultant depressed cardiac output and symptoms of dyspnea and fatigue. In addition, the consequent stasis of blood, with enhanced platelet aggregation and coagulation, 1 predisposes to the formation of atrial thrombi and subsequent clinical thromboembolism.
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For patients presenting with their first episode of atrial fibrillation, transthoracic (surface) echocardiography is often helpful for initial evaluation and management. Many cardiac disorders associated with atrial fibrillation, including mitral valve disease, hypertensive heart disease (left ventricular 9 5 c h a p t e r 9 5 hypertrophy), or ischemic heart disease (focal left ventricular systolic dysfunction) are readily diagnosed by transthoracic echocardiography. Information regarding left ventricular systolic function is of assistance for guiding the choice of ventricular rate controlling agent. Finally, the absence of both clinical risk factors and structural heart disease on transthoracic echocardiography identifies patients for whom chronic therapy with aspirin (versus warfarin) may be preferred.
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Because of its frequent inability to adequately image the left atrial appendage, however, transthoracic echocardiography is not advocated for the identification or exclusion of atrial thrombi.
Although it is inadequate for visualizing atrial thrombi, transthoracic echocardiography is an excellent technique for assessment of left atrial size. Left atrial enlargement is common among patients with atrial fibrillation.
4 Sustained (chronic) atrial fibrillation is associated with progressive biatrial enlargement.
5 Cardioversion and maintenance of sinus rhythm reverse this process. [6] [7] [8] [9] Data are conflicting on the relationship between mild or moderate left atrial enlargement and long-term maintenance of sinus rhythm.
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Because of this uncertainty, we do not include left atrial enlargement alone as an absolute criterion to forgo an attempt at cardioversion. We generally attempt cardioversion for most patients who present with their first episode of atrial fibrillation (assuming the duration of atrial fibrillation is brief, and reversible causes of atrial fibrillation have been treated). Patients with persistent (more than 1 year) atrial fibrillation, rheumatic mitral valve disease, or a left atrial dimension of more than 6.0 cm are less likely to have long-term maintenance of sinus rhythm. Repeated transthoracic echocardiographic studies are not indicated for those with recurrent or chronic atrial fibrillation (unless there is a change in their clinical status, e.g., new heart failure).
Efficacy of Warfarin Before Elective Cardioversion
Though the benefit of repeated cardioversion with rhythmcontrolling agents for relatively asymptomatic patients who are well rate controlled has been shown to be detrimental, 14, 15 many patients are symptomatic and it remains difficult to control their rate. For these patients, successful cardioversion may be associated with clinical thromboembolism, most commonly during the first 10 days after conversion.
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Patients with atrial fibrillation for at least 2 days have a 6% risk of a cardioversion-related clinical thromboembolism if cardioversion is not preceded by 3 to 4 weeks of warfarin [17] [18] [19] [20] [21] (Table 95 .1). The use of a month of prophylactic warfarin [international normalized ratio (INR) 2.0 to 3.0] reduces this risk to less than 1% [17] [18] [19] [21] [22] [23] [24] [25] [26] (Table 95 .2). Although warfarin prophylaxis offers the advantage of a reduction in postcardioversion thromboembolism, this approach delays cardioversion for the vast majority of patients who might otherwise undergo early cardioversion without complication. This delay exposes most patients to prolonged pre-cardioversion warfarin therapy (with associated risk of hemorrhagic complications), and also serves to prolong duration of atrial fibrillation before cardioversion.
Among those receiving warfarin in preparation for elective cardioversion, major hemorrhagic complications requiring hospitalization, blood transfusion, or urgent surgery is reported in 1% to 2% of patients. 18, 22, 25, 27 For these patients, warfarin is often fully reversed to minimize further morbidity, but if the event occurs before elective cardioversion, the patient remains unprotected and in atrial fibrillation. Minor complications (epistaxis, hematuria, menorrhagia) have been reported in an additional 6% to 18% of patients. 18, 22, 25 For such patients, the clinician is faced with the difficult choice of reducing the intensity of anticoagulation, often to a subtherapeutic range (with the patient still in atrial fibrillation) or continuing warfarin at the risk of continued or worsening hemorrhage.
Finally, though 3 to 4 weeks of warfarin are recommended prior to elective cardioversion, many patients are not treated in this manner. In one study, at least 25% of warfarin-eligible patients did not receive 1 month of prophylactic warfarin prior to cardioversion. 28 The proportion of elderly patients who do not receive 1 month of prophylactic warfarin may exceed 50%. 29 Even among patients for whom 1 month of warfarin is intended, transient subtherapeutic prothrombin times are common, 24 with preliminary data suggesting a risk for left atrial thrombus similar to those who had not received any warfarin. 30 For these patients, a strategy of increasing the warfarin dose and restarting the 1-month clock is generally prescribed. 
